Immunology Insights

News, strategy, and signals in immunologic care.

PsO PsA Lupus Crohn's disease UC

Bimzelx Delivers Five-Year Skin Clearance in Psoriasis

Bimzelx maintains PASI 100 in nearly 68% of psoriasis patients through 5 years.

Simponi Aria Faces Biosimilar Competition with AVT05 Filing

FDA accepts biosimilar application for Simponi Aria, setting stage for 2026 market entry.

Saphnelo Slows Organ Damage in Real-World Lupus Cohort

Saphnelo shows reduced long-term organ damage in real-world lupus study.

Skyrizi Achieves Long-Term Clearance in Genital and Scalp Psoriasis

Skyrizi shows 1-year efficacy in genital and scalp PsO, delivering high clearance rates.

Tremfya Offers SC Induction in UC With ASTRO Trial Success

Tremfya SC induction proves effective in UC, offering flexibility.

Tremfya Sustains Remission in Ulcerative Colitis Through 2 Years

Tremfya maintains UC remission through 92 weeks with consistent safety.

Tremfya Demonstrates Superiority to Stelara in CD

GALAXI trials show Tremfya outperforms Stelara in Crohn’s disease.

Tremfya Approved by FDA for Crohn’s Disease

FDA approves Tremfya for Crohn’s disease, solidifying IL-23 footprint in IBD.

Taltz Maintains Cardiovascular Safety in Long-Term Use

Taltz maintains low MACE risk in real-world PsO/PsA patients; long-term safety reinforced.

Benlysta Shows Renal Benefit in Real-World LN Patients

Benlysta improves renal outcomes in real-world lupus nephritis, supporting early biologic use.

Saphnelo Begins Phase III Testing in Lupus Nephritis

AstraZeneca begins Phase III IRIS trial of Saphnelo in lupus nephritis, targeting label expansion.

Bimzelx Demonstrates 3-Year Durability in PsA and axSpA

Bimzelx delivers durable efficacy across PsA and axSpA through 3 years per EULAR 2025 data.

Tremfya Inhibits Structural Joint Damage in PsA

EULAR 2025 APEX study shows Tremfya halts joint damage progression in PsA, a first for IL-23 class.